EMBO Mol Med

PubMed DOI Crossref

Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma.

Mohlin S, Hansson K, Radke K, ..., von Stedingk K, Bexell D

pmc GEO

EMBO Mol Med 11 (8) e10058 [2019-08-00; online 2019-07-16]

NGI Uppsala (Uppsala Genome Center) [Service] National Genomics Infrastructure [Service] Targeted and Structural Proteomics [Service]

DOI Crossref

Anti‐tumor effects of PIM / PI 3K/ mTOR triple kinase inhibitor IBL ‐302 in neuroblastoma

Mohlin S, Hansson K, Radke K, ..., Stedingk K, Bexell D

EMBO Mol Med - (-) - [2019-07-16; online 2019-07-16]

NGI Uppsala (Uppsala Genome Center) [Service] National Genomics Infrastructure [Service]

PubMed DOI Crossref

Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies.

Ayoglu B, Chaouch A, Lochmüller H, ..., Nilsson P, Al-Khalili Szigyarto C

pii pmc

EMBO Mol Med 6 (7) 918-936 [2014-07-00; online 2014-06-13]

Plasma Profiling [Collaborative]

PubMed DOI Crossref

CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer.

Cepeda D, Ng HF, Sharifi HR, ..., Larsson LG, Sangfelt O

pmc

EMBO Mol Med 5 (7) 1067-1086 [2013-07-00; online 2013-06-19]

Tissue Profiling